Results 131 to 140 of about 4,690 (200)

Understanding beliefs about elexacaftor-tezacaftor-ivacaftor therapy in adults living with cystic fibrosis. [PDF]

BMJ Open Respir Res
O'Leary C, Vinh A, Lea-Davies M, Weinman J, Horne R, Duckers J.   +5 more
europepmc   +1 more source

Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor. [PDF]

J Clin Transl Endocrinol
Burnet E, Grunewald D, Larger E, Camus-Bablon F, Eisenhauer C, Mifsud F, Martin C, Honoré I, Kanaan R, Carlier N, Fesenbeckh J, Mosnier-Pudar H, Burgel PR.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Lancet Respiratory Medicine,the
Summary Background The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis.
C. Keating, L. Yonker, F. Vermeulen, Dario Prais, Rachel W. Linnemann, A. Trimble, T. Kotsimbos, J. Mermis, Andrew T Braun, M. O'Carroll, S. Sutharsan, Bonnie W Ramsey, M. Mall, J. Taylor-Cousar, E. McKone, Elizabeth Tullis, T. Floreth, P. Michelson, P. Sosnay, N. Nair, Rachel Zahigian, H. Martin, N. Ahluwalia, A. Lam, A. Horsley   +24 more
exaly   +2 more sources

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Lancet Respiratory Medicine,the
BACKGROUND Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and Drug Administration (FDA) for people with cystic fibrosis with
Pierre-Régis Burgel, I. Sermet-Gaudelus, E. Girodon, Isabelle Durieu, V. Houdouin, Camille Audousset, J. Macey, Dominique Grenet, Michele Porzio, Marlène Murris-Espin, P. Reix, Mélisande Baravalle, Chantal Belleguic, Laurent Mely, Juliette Verhille, Laurence Weiss, Martine Reynaud-Gaubert, M. Mittaine, R. Hamidfar, Sophie Ramel, L. Cosson, Benoît Douvry, Isabelle Danner-Boucher, P. Foucaud, C. Roy, Espérie Burnet, C. Raynal, M. Audrézet, J. da Silva, Clémence Martin   +29 more
exaly   +2 more sources

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis

European Respiratory Journal, 2023
Background Recent studies demonstrated that the triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) improves lung function and reduces pulmonary exacerbations in cystic ...
L. Schaupp, A. Addante, M. Völler, K. Fentker, A. Kuppe, M. Bardua, J. Duerr, L. Piehler, J. Röhmel, Stephanie Thee, Marieluise Kirchner, M. Ziehm, D. Lauster, R. Haag, M. Gradzielski, M. Stahl, Philipp Mertins, S. Boutin, S. Graeber, M. Mall   +19 more
semanticscholar   +1 more source

Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.

American Journal of Respiratory and Critical Care Medicine, 2021
RATIONALE Elexacaftor-tezacaftor-ivacaftor is a cystic fibrosis transmembrane conductance regulator modulator combination, developed for cystic fibrosis (CF) patients with at least one Phe508del mutation.
P. Burgel, I. Durieu, R. Chiron, S. Ramel, I. Danner-Boucher, A. Prevotat, D. Grenet, C. Marguet, M. Reynaud‐Gaubert, J. Macey, L. Mély, A. Fanton, S. Quêtant, L. Lemonnier, J. Paillasseur, J. da Silva, Clémence Martin   +16 more
semanticscholar   +1 more source

Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy

Journal of Cystic Fibrosis, 2022
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta) is the newest Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drug approved by the Food and Drug Administration. Post-marketing reports with earlier CFTR modulators suggest these medications can impact mood, and in clinical trials an adverse effect of headache was reported ...
Suyeon Heo, David C. Young, Julie Safirstein, Brian Bourque, Martine H. Antell, Stefanie Diloreto, Shannon M. Rotolo   +6 more
openaire   +2 more sources

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy

Archives of Gynecology and Obstetrics, 2023
Management of cystic fibrosis has recently stepped forward with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, although data on potential adverse effects are lacking for many categories of patients, such as pregnant women.We report one of the first reports on the outcome of pregnancy in a woman treated with ...
Giuseppe Cimino, Sara Sorrenti, Manuel Murciano, Paola Galoppi, Fiorentina Ascenzioni, Bruno Botta, Roberto Brunelli, Luca Cavinato, Andrea Cerrato, Gabriele Cianfoni, Valentina D’Ambrosio, Francesca De Luca, Paola Delporto, Maria Di Chiara, Paola Galoppi, Francesco Gasparrini, Francesca Ghirga, Antonella Giancotti, Aldo Laganà, Giulia Mazzoccanti, Alessandro Mondo, Carmela Maria Montone, Manuel Murciano, Francesco Pecorini, Maria Grazia Piccioni, Damiana Pompeo, Lorenzo Spiniello, Gianluca Terrin, Patrizia Troiani, Fabrizio Zullo   +29 more
openaire   +3 more sources

The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant

European Respiratory Journal, 2023
Background The European Medicines Agency has approved the cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) for people with cystic fibrosis (CF) carrying at least one F508del variant ...
P. Burgel, I. Sermet-Gaudelus, I. Durieu, R. Kanaan, J. Macey, D. Grenet, M. Porzio, N. Coolen-Allou, R. Chiron, C. Marguet, B. Douvry, N. Dufeu, I. Danner-Boucher, P. Foucaud, L. Lemonnier, E. Girodon, J. da Silva, Clémence Martin, Claire Pascaline Bénédicte Julie Sylvie Benoit Natacha An Andrejak Priou Richaud-Thiriez Macey Montcouquiol   +18 more
semanticscholar   +1 more source

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles.

American Journal of Respiratory and Critical Care Medicine, 2021
RATIONALE The CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to improve clinical outcomes and sweat chloride concentration (SCC) in patients with cystic fibrosis (CF) and one or two F508del alleles.
S. Graeber, C. Vitzthum, S. Pallenberg, L. Naehrlich, M. Stahl, A. Rohrbach, M. Drescher, R. Minso, F. Ringshausen, C. Rueckes-Nilges, J. Klajda, J. Berges, Yin Yu, H. Scheuermann, S. Hirtz, O. Sommerburg, A. Dittrich, B. Tümmler, M. Mall   +18 more
semanticscholar   +1 more source